Recent Updates
Recently added Catalysts
NKTR Positive Sentiment

Nektar Announces Publication in The Lancet of Positive Phase 2b REZOLVE-AD 16-Week Induction Results of Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis

Tuesday, August 25, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Nektar Therapeutics announced positive results from the Phase 2b REZOLVE-AD study, which evaluated rezpegaldesleukin in patients with moderate-to-severe atopic dermatitis. The study successfully met all primary and key secondary endpoints, indicating significant efficacy. This trial is notable for being the first large, placebo-controlled study to support T-reg modulation as a therapeutic approach.

Market Sentiment Analysis

POSITIVE FACTORS

  • REZOLVE-AD study met all primary and key secondary endpoints.
  • First large, placebo-controlled trial supporting T-reg modulation.
  • Demonstrated significant efficacy in treating moderate-to-severe atopic dermatitis.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+186%
120-day peak, hindsight
Typical move
10.2%
average across 4 past catalysts
Cash runway
~40 mo
Minimal dilution risk
Lead asset
Rezpegaldesleukin
Phase 3 · Moderate-to-Severe Atopic Dermatitis

Full Press Release Details

REZOLVE-AD study met all primary and key secondary endpoints, including EASI -75, EASI -90, Itch NRS, vIGA-AD and BSA, on rezpegaldesleukin 24 µg/kg q2w First large, placebo-controlled trial to support T-reg modulation as a clinical mechanism for immunoregulation of chronic inflammatory disease

Frequently Asked Questions

What were the results of the REZOLVE-AD study?

The REZOLVE-AD study met all primary and key secondary endpoints.

What is rezpegaldesleukin used for?

Rezpegaldesleukin is evaluated for treating moderate-to-severe atopic dermatitis.

What is significant about the REZOLVE-AD trial?

It is the first large, placebo-controlled trial supporting T-reg modulation.

What endpoints were achieved in the study?

Endpoints included EASI -75, EASI -90, Itch NRS, vIGA-AD, and BSA.

ShareAdd on Google
Tags: NKTR Viatris Investor Conferences Healthcare Nektar rezpegaldesleukin atopic dermatitis REZOLVE-AD clinical trial
Last updated: Aug 25, 2026

Biotech snapshot

Cash runway
$1023M liquidity · $25M/mo burn
~40 mo
Minimal dilution risk
Lead asset
RezpegaldesleukinPhase 3
Moderate-to-Severe Atopic Dermatitis →

Catalyst track record

+186%
best trade around NKTR's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for NKTR.

See every catalyst's timing & PoA →